CXCL16 and gastrointestinal stromal tumor: Due to the increased expression of CXCL16 within the tumor development, a higher expression of this protein is associated with worse overall survival for a patient with cervical cancer (p = 0.089) [125], stage III/IV colorectal cancer [172], Ewing sarcoma family tumor [126], gastrointestinal stromal tumors [107], lung cancer [28], ovarian carcinoma [128,180] and prostate cancer (Table 3) [108].